Last edition
News about "cutaneous squamous cell carcinoma"
Sun Pharma to Acquire Checkpoint Therapeutics
Checkpoint has received approval from the US Food & Drug Administration (FDA) for UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation.
Cutaneous Squamous Cell Carcinoma | 10/03/2025 | By Aishwarya | 149
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members